Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06355505Recruiting
Study on advanced practice nursing in France
This study looks at how Advanced Practice Nursing (APN) is developing in France. It involves surveys for students and case studies for nurses already working as APNs.
Clichy, FranceAges 18 years+ - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT06329869RecruitingPhase 2
A study of sacituzumab govitecan for advanced esophageal cancer
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
TaipeiAges 18 years+ - NCT06212076RecruitingPhase 1/Phase 2
Testing IPG1094 for advanced solid tumors
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06297525RecruitingPhase 1
Testing STP938 for advanced solid tumors
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
St. Petersburg, FloridaAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT06311578RecruitingPhase 1
Study of JNJ-87704916 alone or with other drugs for advanced solid tumors
This trial tests a new drug, JNJ-87704916, given alone or with other treatments for people with advanced solid tumors that have stopped responding to standard therapies. It may be an option if you have a tumor that can be injected and are in good overall health.
New York, New YorkAges 18 years+ - NCT06298734Recruiting
Exercise and diet study for melanoma patients on immunotherapy
This study tests whether adding high-intensity exercise and a high-fiber diet can improve how well immunotherapy works for people with melanoma. It might help you if you are already on immunotherapy and are not currently very active or eating a lot of fiber.
Boston, MassachusettsAges 18 years+ - NCT06305715RecruitingPhase 2
Radiation before targeted therapy for advanced lung cancer
This trial tests if giving radiation to the main lung tumor before starting a targeted therapy pill can help delay the cancer from growing. It is for people with advanced non-small cell lung cancer that has a specific genetic change and who have not had targeted therapy before.
Milwaukee, WisconsinAges 18 years+ - NCT06315257RecruitingPhase 1
PVX7 vaccine for advanced cervical cancer
This trial tests a new immunotherapy vaccine called PVX7 for women with advanced cervical cancer that is caused by HPV. It aims to see if the vaccine can help prevent the cancer from coming back after standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT06301438Recruiting
Dalpiciclib for HR+/HER2- advanced breast cancer
This trial tests a drug called Dalpiciclib for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). It aims to see if it can help stop the cancer from growing.
ShanghaiAges 18 years+ - NCT06296797Recruiting
Learning about permanent birth control options
This study asks people who want to avoid future pregnancy about their views on permanent birth control methods. It may help doctors provide better information to patients.
San Francisco, CaliforniaAges 21–45 - NCT05037331Recruiting
Osimertinib for advanced EGFR-mutated lung cancer
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
SingaporeAges 21–99 - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Duarte, CaliforniaAges 18 years+ - NCT06276491RecruitingPhase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
Duarte, CaliforniaAges 15 years+ - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06292299Recruiting
Breathing monitor study for children with sleep or breathing issues
This study looks at how well a new breathing monitor works for children with sleep problems, breathing pauses in newborns, or epilepsy. It may help doctors better understand breathing patterns without extra needles or blood tests.
Glasgow, Glasgow CityAges 1 minute–16 years - NCT06285500Recruiting
Single patient cancer treatment study
This study creates a unique treatment plan based on the genetic changes found in your tumor. A team of experts will review your cancer's molecular profile to decide the best next therapy for you, even if standard options are not clear.
Toronto, OntarioAges 18 years+ - NCT06292169Recruiting
Comparing two ways to release a muscle in reverse shoulder replacement
This trial tests if releasing a small chest muscle (the pectoralis minor) during reverse total shoulder replacement leads to better recovery or pain relief compared to not releasing it.
Atlanta, GeorgiaAges 18 years+ - NCT06291987RecruitingPhase 1
Ivosidenib with ruxolitinib for advanced MPN with IDH1 mutation
This trial tests a combination of two targeted drugs, ivosidenib and ruxolitinib, for people with advanced myeloproliferative neoplasms (MPNs) that have an IDH1 gene mutation. The goal is to see if this treatment can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT05956587RecruitingPhase 2
Testing two study drugs for advanced lung cancer and other tumors
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06008054RecruitingPhase 2
New drug combo for advanced gastrointestinal cancers
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.